Clinical trial · Interventional
Anti-recurrence Treatment of Postresection on HCC Patients With MVI Presence and Over-expression of ASPH
Anti-recurrence Treatment of Postresection on Hepatocellular Carcinoma Patients With Microvascular Invasion Presence and Over-expression of Aspartate Beta-hydroxylase: A Randomized Controlled Study
NCT02587884CI-TRIAL-00021578unknownPhase 1ClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The aim of this study is to explore the effect of Transarterial Chemoembolization (TACE) on the prognosis of patients with microvascular invasion presence(MVI) and overexpression of Aspartate-β-hydroxylase(ASPH).
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Hepatocellular Carcinoma | Hepatocellular Carcinoma | ONTOLOGY_EXACT | 0.98 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| TACE | Procedure | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- type
- ACTIVE_COMPARATOR
- label
- Group TACE
- description
- Patients will treated with TACE after resection.
- interventionNames
- Procedure: TACE
- type
- NO_INTERVENTION
- label
- Group Control
- description
- Patients will treated without TACE after resection.
Primary outcomes (1)
- measure
- Overall Survival
- timeFrame
- 3 years
Secondary outcomes (1)
- measure
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
- Maximum age
- 70 Years
Show eligibility criteria text
Inclusion Criteria: 1. Via clinical diagnosis and confirm it is primary liver cancer 2. Pathological evidence of HCC 3. Confirm presence of MVI and over-expression of ASPH after opreation 4. Within Milan criteria 5. Estimate tumor can gain treatment of curing operation 6. No evidence for extrahepatic metestasis 7. liver function ：Child-Pugh A/B Exclusion Criteria: 1. Reject to attend 2. Impossible to come to our hospital for physical examination regularly 3. Patients with apparent cardiac, pulmonary, cerebral and renal dysfunction 4. Female with pregnancy or during the lactation period
References
Publications (0)
Data not yet available
No reference posted for this study.